Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial
- PMID: 30646965
- PMCID: PMC6334401
- DOI: 10.1186/s13063-018-3169-3
Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial
Erratum in
-
Correction to: Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial.Trials. 2019 Jun 20;20(1):368. doi: 10.1186/s13063-019-3519-9. Trials. 2019. PMID: 31221222 Free PMC article.
Abstract
Background: Gabapentin has shown efficacy in the treatment of chronic neuropathic or mixed pain in adults. Although pediatric pain specialists have extensive experience with gabapentin for the treatment of neuropathic pain, its use is off-label. Its efficacy and safety in this context have never been shown. The aim of this trial is to compare gabapentin with placebo as add-on to morphine for the treatment of severe chronic mixed or neuropathic pain in children. This trial is part of the European Union Seventh Framework Programme project Gabapentin in Paediatric Pain (GAPP) to develop a pediatric use marketing authorization for a new gabapentin suspension.
Methods/design: The GAPP-2 study is a randomized, double-blind, placebo-controlled, multicenter superiority phase II study in children with severe chronic neuropathic or mixed pain. Its primary objective is to evaluate the efficacy of a gabapentin liquid formulation as adjunctive therapy to morphine. Sixty-six eligible children 3 months to 18 years of age with severe pain (pain scores ≥ 7), stratified in three age groups, will be randomized to receive gabapentin (to an accumulating dose of 45 to 63 mg/kg/day, dependent on age) or placebo, both in addition to morphine, for 12 weeks. Randomization will be preceded by a short washout period, and treatment will be initiated by a titration period of 3 weeks. After the treatment period, medication will be tapered during 4 weeks. The primary endpoint is the average pain scores in the two treatment groups (average of two measures each day for 3 days before the end-of-study visit [V10] assessed by age-appropriate pain scales (Face, Legs, Activity, Cry, Consolability scale; Faces Pain Scale-Revised; Numeric Rating Scale). Secondary outcomes include percentage responders to treatment (subjects with 30% reduction in pain scale), number of episodes of breakthrough pain, number of rescue interventions, number of pain-free days, participant dropouts, quality of life (Pediatric Quality of Life Inventory), and acceptability of treatment. Outcomes will be measured at the end-of-study visit after 12 weeks of treatment at the optimal gabapentin dose. Groups will be compared on an intention-to-treat basis.
Discussion: We hope to provide evidence that the combination of morphine and gabapentin will provide better analgesia than morphine alone and will be safe. We also aim to obtain confirmation of the recommended pediatric dose.
Trial registration: EudractCT, 2014-004897-40 . Registered on 7 September 2017. ClinicalTrials.gov, NCT03275012 . Registered on 7 September 2017.
Keywords: Children; Gabapentin; Neuropathic pain; Pharmacokinetics.
Conflict of interest statement
Ethics approval and consent to participate
Ethical approval was obtained from the Medical Ethical Committee of the Erasmus Medical Centre, Rotterdam, The Netherlands. Medical ethical review is under way in the other participating centers (EudractCT, 2014-004897-40), and registered at ClinicalTrials.gov (NCT03275012).
Consent for publication
Full consent for publication was given by the GAPP consortium.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures
Similar articles
-
Non-inferiority double-blind randomised controlled trial comparing gabapentin versus tramadol for the treatment of chronic neuropathic or mixed pain in children and adolescents: the GABA-1 trial-a study protocol.BMJ Open. 2019 Feb 20;9(2):e023296. doi: 10.1136/bmjopen-2018-023296. BMJ Open. 2019. PMID: 30787078 Free PMC article. Clinical Trial.
-
Morphine, gabapentin, or their combination for neuropathic pain.N Engl J Med. 2005 Mar 31;352(13):1324-34. doi: 10.1056/NEJMoa042580. N Engl J Med. 2005. PMID: 15800228 Clinical Trial.
-
Is intravenously administered, subdissociative-dose KETAmine non-inferior to MORPHine for prehospital analgesia (the KETAMORPH study): study protocol for a randomized controlled trial.Trials. 2018 May 2;19(1):260. doi: 10.1186/s13063-018-2634-3. Trials. 2018. PMID: 29716637 Free PMC article.
-
Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23. Pain Pract. 2008. PMID: 18503626
-
Oxycodone for neuropathic pain and fibromyalgia in adults.Cochrane Database Syst Rev. 2014 Jun 23;(6):CD010692. doi: 10.1002/14651858.CD010692.pub2. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2016 Jul 28;7:CD010692. doi: 10.1002/14651858.CD010692.pub3. PMID: 24956205 Updated. Review.
Cited by
-
Effect of patient-controlled intravenous analgesia combined with flurbiprofen axetil and dezocine on postoperative analgesia for lobectomy (EPIC-FAD): a trial protocol.Trials. 2021 Mar 1;22(1):175. doi: 10.1186/s13063-021-05108-9. Trials. 2021. PMID: 33648558 Free PMC article.
-
Management of cancer pain with analgetic adjuvant and weak opioid in prostate cancer bone metastases: A case series.Ann Med Surg (Lond). 2020 Nov 9;60:575-578. doi: 10.1016/j.amsu.2020.10.070. eCollection 2020 Dec. Ann Med Surg (Lond). 2020. PMID: 33299563 Free PMC article.
-
Prospective randomized trial of interventions for vincristine-related neuropathic pain.Pediatr Blood Cancer. 2020 Sep;67(9):e28539. doi: 10.1002/pbc.28539. Epub 2020 Jul 2. Pediatr Blood Cancer. 2020. PMID: 32618122 Free PMC article. Clinical Trial.
-
Correction to: Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial.Trials. 2019 Jun 20;20(1):368. doi: 10.1186/s13063-019-3519-9. Trials. 2019. PMID: 31221222 Free PMC article.
References
-
- Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2006;(3):CD006146. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical